Mechanisms · Mechanism of Action
BDNF & GDNF Upregulation
Ibogaine and noribogaine upregulate brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), driving downstream neuroplasticity and dopaminergic repair.
Quick Answer
What is bdnf & gdnf upregulation in ibogaine pharmacology?
Reviewed by Dr. Arellano, M.D. — May 2026
What BDNF and GDNF do
BDNF (brain-derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) are neurotrophins — proteins that promote neuron survival, axon growth, and synaptic plasticity in the central nervous system.
BDNF acts broadly across cortical and hippocampal circuits and is the most-studied neurotrophin in depression research. GDNF is more selective for dopaminergic neurons in the ventral tegmental area (VTA) and substantia nigra, which is why it is implicated in both Parkinson's disease research and addiction research.
Ibogaine's effect on GDNF
He et al. (2005) demonstrated that ibogaine upregulates GDNF mRNA and protein expression in the VTA of rodent models, with GDNF persisting beyond the timeframe in which ibogaine and noribogaine remain detectable in plasma.
Subsequent work (Marton et al. 2019; Carnicella & Ron 2009) suggests this GDNF surge is responsible for the long-tail anti-craving effect: the neurotrophic signal continues to drive dopaminergic repair after the parent drug clears.
Ibogaine's effect on BDNF
BDNF upregulation has been observed across multiple psychedelic and dissociative compound classes (psilocybin, ketamine, ibogaine), supporting the broader hypothesis that these compounds share a final-common-pathway neuroplasticity mechanism.
Olson (2018) and follow-on work positions ibogaine within the "psychoplastogen" class — compounds that produce rapid, sustained changes in synaptic structure and function via TrkB signaling.
Why this matters clinically
Patients with chronic opioid use disorder, treatment-resistant depression, or Parkinson's disease have measurable deficits in dopaminergic and serotonergic circuit integrity. A single therapeutic intervention that upregulates GDNF and BDNF over weeks-to-months may explain the durable post-flood-dose responses observed in open-label cohorts (Mash 2018; Cherian 2024).
This is also why MindScape positions ibogaine as a circuit-repair intervention with structured integration — not a one-time withdrawal interrupter.
Targets
- BDNF
- GDNF
- TrkB receptor
- Ret receptor
- Dopaminergic neurons (VTA)
- Serotonergic neurons
Citations & Reading
- He DY, et al. (2005). The Journal of Neuroscience, 25(3), 619-628.
- Marton S, et al. (2019). Frontiers in Pharmacology, 10, 193.
- Carnicella S, Ron D. (2009). Pharmacology & Therapeutics, 124(2), 198-205.
- Olson DE. (2018). ACS Chemical Neuroscience, 9(10), 2438-2447.
For broader clinical context, see the 2026 evidence-base review and the onsite taper cohort methodology page.
Related mechanisms
Mu-Opioid Receptor
Ibogaine and noribogaine interact with the mu-opioid receptor at low affinity — but the clinical effect on opioid withdrawal is multifactorial, not a simple substitute-and-taper.
NMDA Receptor Antagonism
Ibogaine is a non-competitive NMDA receptor antagonist — a mechanism it shares with ketamine, dextromethorphan, and memantine, with implications for tolerance reversal and dissociative experience.
Noribogaine — The Long-Tail Metabolite
Noribogaine is ibogaine's CYP2D6-formed metabolite — cleaner mu-opioid partial-agonist profile, lower hERG signal, longer half-life. The molecule that drives the post-flood-dose tail.
Ibogaine Pharmacokinetics
Absorption, CYP2D6 metabolism to noribogaine, distribution, and elimination — including the long noribogaine tail that drives the post-flood telemetry window.